 |
0 Diseases |  |
137 Trials |
|
137 Trials |  |
5343 News |  |
| «12...79808182838485868788899091» |
- | Trial completion date, Trial primary completion date: BISER: Bacteriology and Inflammation in Bronchiectasis (clinicaltrials.gov) - Aug 28, 2018
P=N/A, N=80, Recruiting, Sponsor: Guangzhou Institute of Respiratory Disease
Trial completion date: Dec 2017 --> Dec 2020 | Trial primary completion date: Dec 2017 --> Dec 2020
- | Orapenem (tebipenem pivoxil) / Meiji Seika, GSK
Trial completion: Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994 (clinicaltrials.gov) - Aug 28, 2018
P1, N=124, Completed, Sponsor: Spero Therapeutics
Trial completion date: Dec 2017 --> Dec 2020 | Trial primary completion date: Dec 2017 --> Dec 2020 Recruiting --> Completed
- | Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date: REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - Aug 20, 2018
P4, N=6800, Recruiting, Sponsor: MJM Bonten
Recruiting --> Completed N=4000 --> 6800 | Trial completion date: Feb 2019 --> Jun 2022 | Trial primary completion date: Feb 2019 --> Dec 2021 | Initiation date: Dec 2015 --> Apr 2016
- | New trial: Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis (clinicaltrials.gov) - Aug 15, 2018
P=N/A, N=800, Recruiting, Sponsor: Beijing Children's Hospital
- | levofloxacin / Generic mfg., trimethoprim/sulfamethoxazole / Generic mfg., azithromycin / Generic mfg.
Trial completion date, Trial primary completion date: Fluoroquinolone Associated Disability (clinicaltrials.gov) - Aug 13, 2018
P=N/A, N=100, Recruiting, Sponsor: Janssen Research & Development, LLC
N=4000 --> 6800 | Trial completion date: Feb 2019 --> Jun 2022 | Trial primary completion date: Feb 2019 --> Dec 2021 | Initiation date: Dec 2015 --> Apr 2016 Trial completion date: Jul 2018 --> Dec 2018 | Trial primary completion date: Jul 2018 --> Dec 2018
- | colistin sulphate / Generic mfg.
New P2/3 trial: The Effect of Colistin Inhalation on Ventilator Associated Pneumonia (clinicaltrials.gov) - Aug 9, 2018
P2/3, N=40, Completed, Sponsor: Nourhan Hassan Osama Thuraya Mohamed
- | Trial completion: Tailored Therapy for Helicobacter Pylori Rescue Treatment (clinicaltrials.gov) - Aug 7, 2018
P4, N=200, Completed, Sponsor: Shanghai Jiao Tong University School of Medicine
Trial completion date: Jul 2018 --> Dec 2018 | Trial primary completion date: Jul 2018 --> Dec 2018 Recruiting --> Completed
- | PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P4 trial, Pneumococcal vaccines: Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents (clinicaltrials.gov) - Aug 7, 2018
P4, N=40, Enrolling by invitation, Sponsor: Minsk State Clinical Hospital No 9
- | levofloxacin / Generic mfg., voriconazole / Generic mfg.
New trial: Prevention of Oral Mucositis After Using Oral Topical Vitamin E Versus Voriconazole and Levofloxacin in Pediatric Cancer Patients Receiving Chemotherapy (clinicaltrials.gov) - Aug 3, 2018
P=N/A, N=15, Enrolling by invitation, Sponsor: Cairo University
- | AzaSite (1% azithromycin ophthalmic solution) / Sun Pharma, Akorn, Nicox
Trial completion date, Trial primary completion date: Healthy Patients & Effect of Antibiotics (clinicaltrials.gov) - Jul 24, 2018
P=N/A, N=20, Active, not recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Completed Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019
- | levofloxacin / Generic mfg., azacitidine / Generic mfg.
New P3 trial: AZABAC: Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients (clinicaltrials.gov) - Jul 19, 2018
P3, N=150, Recruiting, Sponsor: Centre Henri Becquerel
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma, Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Kineret (anakinra) / SOBI
New trial: Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants (clinicaltrials.gov) - Jul 15, 2018
P=N/A, N=500, Not yet recruiting, Sponsor: Kevin Watt
- ||| levofloxacin / Generic mfg., norfloxacin / Generic mfg., azithromycin / Generic mfg.
Trial completion, Enrollment change, Adverse events, Serious adverse event: A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events (clinicaltrials.gov) - Jul 6, 2018
P=N/A, N=117911, Completed, Sponsor: Janssen Research & Development, LLC
Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019 Active, not recruiting --> Completed | N=15000 --> 117911
- | New P4 trial: Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication. (clinicaltrials.gov) - Jun 27, 2018
P4, N=400, Not yet recruiting, Sponsor: Shandong University
- | levofloxacin / Generic mfg., tetracycline / Generic mfg.
New P4 trial: Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the Rescue Treatment of Helicobacter Pylori Infection (clinicaltrials.gov) - Jun 20, 2018
P4, N=400, Not yet recruiting, Sponsor: Shandong University
- | levofloxacin / Generic mfg.
New P4 trial: Genotypic Resistance Guided Versus Susceptibility Testing Guided Therapy for the First-line Eradication of H. Pylori (clinicaltrials.gov) - Jun 13, 2018
P4, N=560, Recruiting, Sponsor: National Taiwan University Hospital
- |||||||||| Taigexyn (nemonoxacin) / TaiGen
New P3 trial: Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia (clinicaltrials.gov) - Jun 10, 2018
P3, N=342, Completed, Sponsor: R-Pharm
- ||| levofloxacin / Generic mfg., norfloxacin / Generic mfg., azithromycin / Generic mfg.
New trial, Adverse events, Serious adverse event: A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events (clinicaltrials.gov) - Jun 3, 2018
P=N/A, N=15000, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
- ||| levofloxacin / Generic mfg., trimethoprim/sulfamethoxazole / Generic mfg., azithromycin / Generic mfg.
Enrollment open: Fluoroquinolone Associated Disability (clinicaltrials.gov) - May 31, 2018
P=N/A, N=100, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed | N=15000 --> 117911 Not yet recruiting --> Recruiting
- Sirturo (bedaquiline) / J&J, Pharmstandard
Enrollment closed: An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB) (clinicaltrials.gov) - May 30, 2018
P2, N=6, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| levofloxacin / Generic mfg., trimethoprim/sulfamethoxazole / Generic mfg., azithromycin / Generic mfg.
New trial: Fluoroquinolone Associated Disability (clinicaltrials.gov) - May 27, 2018
P=N/A, N=100, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- || ciprofloxacin oral / Generic mfg., levofloxacin / Generic mfg.
New P1 trial: PRO-174/I: Safety and Tolerability of the PRO-174 Versus Sophix (clinicaltrials.gov) - May 9, 2018
P1, N=30, Recruiting, Sponsor: Laboratorios Sophia S.A de C.V.
- | Trial primary completion date: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - May 2, 2018
P4, N=1786, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2018 --> Jun 2019
- | prednisolone / Generic mfg., levofloxacin / Generic mfg.
Trial completion date, Trial primary completion date: Effects of Oral Steroid in Mycoplasma Pneumoniae Pneumonia (clinicaltrials.gov) - Apr 27, 2018
P4, N=80, Recruiting, Sponsor: Seoul National University Hospital
Trial primary completion date: Mar 2018 --> Jun 2019 Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2017 --> Dec 2020
- | Trial completion: Tailored Versus Empiric Therapy for Helicobacter Pylori Treatment (clinicaltrials.gov) - Apr 18, 2018
P4, N=382, Completed, Sponsor: Shanghai Jiao Tong University School of Medicine
Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2017 --> Dec 2020 Active, not recruiting --> Completed
- | Enrollment closed: Tailored Versus Empiric Therapy for Helicobacter Pylori Treatment (clinicaltrials.gov) - Apr 12, 2018
P4, N=382, Active, not recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva
Trial completion, Trial completion date, Trial primary completion date: IGNITE3: Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections (clinicaltrials.gov) - Apr 11, 2018
P3, N=1200, Completed, Sponsor: Tetraphase Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jan 2018 | Trial primary completion date: Dec 2018 --> Dec 2017
- | Trial completion date, Trial primary completion date: APPACIII: Antibiotics vs. Placebo in Acute Uncomplicated Appendicitis (clinicaltrials.gov) - Apr 9, 2018
P=N/A, N=147, Enrolling by invitation, Sponsor: Turku University Hospital
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jan 2018 | Trial primary completion date: Dec 2018 --> Dec 2017 Trial completion date: Aug 2028 --> Aug 2029 | Trial primary completion date: Aug 2018 --> Mar 2019
- | Dexilant (dexlansoprazole) / Takeda
Trial completion: Once Daily Dose Dexlansoprazole Quadruple Therapy for Helicobacter Pylori (clinicaltrials.gov) - Apr 3, 2018
P4, N=180, Completed, Sponsor: Ramathibodi Hospital
Trial completion date: Aug 2028 --> Aug 2029 | Trial primary completion date: Aug 2018 --> Mar 2019 Recruiting --> Completed
- |||||| murepavadin (POL7080) / Spexis
Enrollment open: PRISM-MDR: Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa (clinicaltrials.gov) - Apr 2, 2018
P3, N=150, Recruiting, Sponsor: Polyphor Ltd.
Recruiting --> Completed Not yet recruiting --> Recruiting
- | vancomycin / Generic mfg., levofloxacin / Generic mfg.
Trial completion, Phase classification, Enrollment change, Trial completion date: ANTHEM: Empirical ANtibiotic THErapy in Adults Hospitalised With Malaria (clinicaltrials.gov) - Mar 30, 2018
P, N=20, Completed, Sponsor: Menzies School of Health Research
Not yet recruiting --> Recruiting Recruiting --> Completed | Phase classification: PN/A --> P | N=150 --> 20 | Trial completion date: Apr 2018 --> Jan 2018
- | Lamprene (clofazimine) / Novartis, Sirturo (bedaquiline) / J&J, Pharmstandard
Enrollment open: TRUNCATE-TB: Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis (clinicaltrials.gov) - Mar 29, 2018
P2/3, N=900, Recruiting, Sponsor: University College, London
Recruiting --> Completed | Phase classification: PN/A --> P | N=150 --> 20 | Trial completion date: Apr 2018 --> Jan 2018 Not yet recruiting --> Recruiting
- | Enrollment change, Trial completion date: Tailored Versus Empiric Therapy for Helicobacter Pylori Treatment (clinicaltrials.gov) - Mar 27, 2018
P4, N=322, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Not yet recruiting --> Recruiting N=500 --> 322 | Trial completion date: Dec 2018 --> May 2018
- | Lamprene (clofazimine) / Novartis, Sirturo (bedaquiline) / J&J, Pharmstandard
New P2/3 trial: TRUNCATE-TB: Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis (clinicaltrials.gov) - Mar 21, 2018
P2/3, N=900, Not yet recruiting, Sponsor: University College, London
- || Orapenem (tebipenem pivoxil) / Meiji Seika, GSK
Enrollment change, Trial completion date, Trial primary completion date: Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994 (clinicaltrials.gov) - Mar 20, 2018
P1, N=152, Recruiting, Sponsor: Spero Therapeutics
N=500 --> 322 | Trial completion date: Dec 2018 --> May 2018 N=56 --> 152 | Trial completion date: Jan 2018 --> Aug 2018 | Trial primary completion date: Jan 2018 --> Aug 2018
- | Noxafil (posaconazole) / Merck (MSD)
Trial completion date, Trial primary completion date: Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients (clinicaltrials.gov) - Mar 3, 2018
P=N/A, N=1000, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
N=56 --> 152 | Trial completion date: Jan 2018 --> Aug 2018 | Trial primary completion date: Jan 2018 --> Aug 2018 Trial completion date: Jan 2018 --> Mar 2018 | Trial primary completion date: Jan 2018 --> Mar 2018
- | levofloxacin / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy: Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB (clinicaltrials.gov) - Feb 27, 2018
P2, N=111, Active, not recruiting, Sponsor: Boston University
Trial completion date: Jan 2018 --> Mar 2018 | Trial primary completion date: Jan 2018 --> Mar 2018 Completed --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Mar 2019 | Trial completion date: Jul 2017 --> Mar 2019
- | levofloxacin / Generic mfg.
New trial: Procalcitonin-guided Antibiotic Therapy During Severe Exacerbation of COPD (clinicaltrials.gov) - Feb 20, 2018
P=N/A, N=100, Recruiting, Sponsor: University Hospital, Mahdia
- | levofloxacin / Generic mfg.
Trial initiation date: Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation (clinicaltrials.gov) - Feb 19, 2018
P3, N=740, Completed, Sponsor: Children's Oncology Group
Completed --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Mar 2019 | Trial completion date: Jul 2017 --> Mar 2019 Initiation date: Jun 2011 --> Sep 2011
- | levofloxacin / Generic mfg.
Enrollment open, Trial initiation date: PERFECT: Feasibility of Centralized Therapeutic Drug Monitoring of Fluoroquinolones in Multi-Drug Resistant Tuberculosis Patients (clinicaltrials.gov) - Feb 19, 2018
P=N/A, N=360, Recruiting, Sponsor: University Medical Center Groningen
Initiation date: Jun 2011 --> Sep 2011 Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Feb 2018
- | AzaSite (1% azithromycin ophthalmic solution) / Sun Pharma, Akorn, Nicox
Trial primary completion date: Healthy Patients & Effect of Antibiotics (clinicaltrials.gov) - Jan 29, 2018
P=N/A, N=20, Active, not recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Feb 2018 Trial primary completion date: Dec 2017 --> Jun 2018
- | New P4 trial: Tailored Therapy for Helicobacter Pylori Rescue Treatment (clinicaltrials.gov) - Jan 29, 2018
P4, N=200, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- | azacitidine / Generic mfg.
Enrollment open, Trial initiation date: Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study With Antibacterial Prophylaxis in Azacitidine Treated MDS Patients (clinicaltrials.gov) - Jan 26, 2018
P3, N=170, Recruiting, Sponsor: Sheba Medical Center
Trial primary completion date: Dec 2017 --> Jun 2018 Not yet recruiting --> Recruiting | Initiation date: Dec 2016 --> Aug 2017
- | levofloxacin / Generic mfg.
Trial completion, Trial primary completion date: PK of Levofloxacin in MDR-TB Patients (clinicaltrials.gov) - Jan 25, 2018
P=N/A, N=20, Completed, Sponsor: University Medical Center Groningen
Not yet recruiting --> Recruiting | Initiation date: Dec 2016 --> Aug 2017 Recruiting --> Completed | Trial primary completion date: May 2017 --> Oct 2017
- | levofloxacin / Generic mfg.
New trial: PERFECT: Feasibility of Centralized Therapeutic Drug Monitoring of Fluoroquinolones in Multi-Drug Resistant Tuberculosis Patients (clinicaltrials.gov) - Jan 24, 2018
P=N/A, N=360, Not yet recruiting, Sponsor: University Medical Center Groningen
- |||||||||| murepavadin (POL7080) / Spexis
New P3 trial: PRISM-MDR: Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa (clinicaltrials.gov) - Jan 24, 2018
P3, N=150, Not yet recruiting, Sponsor: Polyphor Ltd.
- | levofloxacin / Generic mfg., amoxycillin/clavulanate / Generic mfg.
Enrollment open, Trial primary completion date: Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: -DALFEN Study (clinicaltrials.gov) - Jan 19, 2018
P3, N=142, Recruiting, Sponsor: All India Institute of Medical Sciences, New Delhi
Recruiting --> Completed | Trial primary completion date: May 2017 --> Oct 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2017 --> Dec 2018
- | levofloxacin / Generic mfg.
Trial completion: Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation (clinicaltrials.gov) - Jan 16, 2018
P3, N=740, Completed, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed
- ||| Orapenem (tebipenem pivoxil) / Meiji Seika, GSK
New P1 trial: Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994 (clinicaltrials.gov) - Jan 10, 2018
P1, N=56, Recruiting, Sponsor: Spero Therapeutics
- | nitazoxanide / Generic mfg.
Trial primary completion date: A Two Week Nitazoxanidebased Quadruple Regimen (clinicaltrials.gov) - Jan 3, 2018
P3, N=100, Recruiting, Sponsor: Tanta University
Active, not recruiting --> Completed Trial primary completion date: Dec 2017 --> Dec 2022